Prevention of OHSS - dopamine agonists

被引：29

作者：

Busso, Cristiano E. ^{[1
]}

Garcia-Velasco, Juan ^{[2
]}

Gomez, Raul ^{[3
]}

Alvarez, Claudio ^{[4
]}

Simon, Carlos ^{[1
,5
]}

Pellicer, Antonio ^{[1
,6
]}

机构：

[1] Inst Valenciano Infertilidad Valencia, Valencia 46015, Spain

[2] Inst Valenciano Infertilidad Madrid, Madrid 28035, Spain

[3] Fd6n Inst Valenciano Infertilidad, Valencia 46015, Spain

[4] Inst Valenciano Infertliclad Santiago Chile, Santiago, Chile

[5] Ctr Invest Principe Felipe, Valencia, Spain

[6] Valencia Sch Med, Dept Pediat Obstet & Gynaecol, Valencia, Spain

来源：

REPRODUCTIVE BIOMEDICINE ONLINE | 2009年 / 19卷 / 01期

关键词：

assisted reproductive technologies; dopamine agonists; ovarian hyperstimulation syndrome; vascular endothelial growth factor; ENDOTHELIAL GROWTH-FACTOR; OVARIAN HYPERSTIMULATION SYNDROME; VASCULAR-PERMEABILITY FACTOR; HUMAN GRANULOSA-CELLS; FACTOR VEGF; CAPILLARY-PERMEABILITY; FACTOR RECEPTOR-1; TYROSINE KINASE; PLASMA-LEVELS; FACTOR GENE;

D O I：

10.1016/S1472-6483(10)60044-2

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Ovarian hyperstimulation syndrome (OHSS) is in iatrogenic complication of ovulation induction, which may seriously affect the patient's health, with 0.1-2.0% of the patients developing severe forms of the syndrome. OHSS signs and symptoms are direct consequences of fluid shift from capillaries to the third space due to increased vascular permeability. The mechanisms of OHSS pathophysiology remain unknown but evidence obtained in animal models prove that vascular endothelial growth factor (VEGF) is directly involved and the inhibition of the VEGF system could prevent OHSS from occurring. Dopamine agonists impede the phosphorylation of the VEGF receptor 2 and reduce the incidence and severity of OHSS with a safe clinical profile. As far as is known, this is the first pathophysiological approach for treatment and prevention of OHSS.

引用

页码：43 / 51

页数：9

共 78 条

[11]

Brekken RA, 2000, CANCER RES, V60, P5117

[12] Expression of messenger ribonucleic acid splice variants for vascular endothelial growth factor in the penis of adult rats and humans [J].

Burchardt, M ;

Burchardt, T ;

Chen, MW ;

Shabsigh, A ;

de la Taille, A ;

Buttyan, R ;

Shabsigh, R .

BIOLOGY OF REPRODUCTION, 1999, 60 (02) :398-404

[13]

Busso C, 2008, HUMAN REPROD S1, V23, pi60

[14] Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome [J].

Chen, CD ;

Wu, MY ;

Chen, HF ;

Chen, SU ;

Ho, HN ;

Yang, YS .

FERTILITY AND STERILITY, 1999, 72 (02) :286-292

[15] A spontaneous and severe hyperstimulation of the ovaries revealing a gonadotroph adenoma [J].

Christin-Maitre, S ;

Rongières-Bertrand, C ;

Kottler, ML ;

Lahlou, N ;

Frydman, R ;

Touraine, P ;

Bouchard, P .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (10) :3450-3453

[16] New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome? [J].

Delbaere, A ;

Smits, G ;

Olatunbosun, O ;

Pierson, R ;

Vassart, G ;

Costagliola, S .

HUMAN REPRODUCTION, 2004, 19 (03) :486-489

[17]

deMola JRL, 1996, HUM REPROD, V11, P1377

[18] THE FMS-LIKE TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR [J].

DEVRIES, C ;

ESCOBEDO, JA ;

UENO, H ;

HOUCK, K ;

FERRARA, N ;

WILLIAMS, LT .

SCIENCE, 1992, 255 (5047) :989-991

[19] Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization [J].

Enskog, A ;

Henriksson, M ;

Unander, M ;

Nilsson, L ;

Brännström, M .

FERTILITY AND STERILITY, 1999, 71 (05) :808-814

[20] DOPAMINE TREATMENT FOR SEVERE OVARIAN HYPERSTIMULATION SYNDROME [J].

FERRARETTI, AP ;

GIANAROLI, L ;

DIOTALLEVI, L ;

FESTI, C ;

TROUNSON, A .

HUMAN REPRODUCTION, 1992, 7 (02) :180-183

← 1 2 3 4 5 6 7 8 →